Sanofi India is currently trading at Rs. 7295.00, up by 17.55 points or 0.24% from its previous closing of Rs. 7277.45 on the BSE.
The scrip opened at Rs. 7276.00 and has touched a high and low of Rs. 7369.00 and Rs. 7176.00 respectively. So far 1412 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 10 has touched a 52 week high of Rs. 9300.00 on 10-Aug-2021 and a 52 week low of Rs. 6949.35 on 27-Jan-2022.
Last one week high and low of the scrip stood at Rs. 7341.40 and Rs. 7074.50 respectively. The current market cap of the company is Rs. 16789.78 crore.
The promoters holding in the company stood at 60.40%, while Institutions and Non-Institutions held 28.27% and 11.33% respectively.
Sanofi India has reported results for quarter and year ended December 31, 2021. The company has reported a fall of 26.50% in its net profit at Rs 90.40 crore for the quarter under review as compared to Rs 123.00 crore for the same quarter in the previous year. Total income of the company decreased by 4.39% at Rs 704.20 crore for December quarter as compared Rs 736.50 crore for the corresponding quarter previous year.
For the year ended December 31, 2021, the company has reported rise of 97.74% in its net profit at Rs 944.40 crore as compared to Rs 477.60 crore for the previous year. Total income of the company increased by 1.31% at Rs 3031.00 crore for the year under review as compared Rs 2991.70 crore for the previous year.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: